New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Adaptimmune Therapeutics plc
ADAP
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

12M

Biotechnology

Next Earning date - 13 May 2025

12M

Biotechnology

Next Earning date - 13 May 2025

0.28USD

Shape-0.17 ( -37.89%)
sun-fogPre-market 0.58$arrow-right-up0.00 (0.01%)
Market Closed (as of Mar 20, 20:00 EDT)
favorite-chart

Relative Strenght

3
favorite-chart

Volume Buzz

799%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

83%

Quote Panel

Shape
Updated March 21, 2025
1W -38.69 % 1M -49.29 % 3M -52.38 % 1Y -80.56 %

Key Metrics

Shape
  • Market Cap

    11.94M


  • Shares Outstanding

    42.65M


  • Share in Float

    37.75M


  • Dividende

    0


  • Earning Date

    13 May 2025


  • Price Target

    0.28


  • Average Volume

    1.54M


  • Beta

    2.511


  • Range

    0.261-1.65


  • Industry

    Biotechnology


  • Website

    https://www.adaptimmune.com


  • Sector

    Healthcare


Fundamentals

Shape

Relative Strength

Shape

ADAP

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$38M

Shape-7%

2025-Revenue

$0.10

Shape-741%

2025-EPS

$38M

Shape-197%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

0.00(-100.00%)

Number of analyst

0

Last analyst upgrade/downgrade

H.C. Wainwright

initialise

Previous: Not converted

2024-07-30

Now: Buy

Scotiabank

initialise

Previous: Not converted

2024-05-30

Now: Outperform

Guggenheim

upgrade

Previous: Not converted

2023-01-03

Now: Buy

Bank of America Securities

upgrade

Previous: Not converted

2022-11-09

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

N/A

-0.18
vs -0.25

Q1.23

arrow
arrow

+103%

0.01
vs -0.32

Q2.23

arrow
arrow

N/A

-0.21
vs -0.28

Q3.23

arrow
arrow

N/A

-0.20
vs -0.24

Q4.23

arrow
arrow

N/A

-0.24
vs -0.18

Q1.24

arrow
arrow

N/A

-0.18
vs 0.01

Q2.24

arrow
arrow

+214%

0.24
vs -0.21

Q3.24

arrow
arrow

N/A

-0.07
vs -0.20

Q4.24

arrow
arrow

N/A

-0.03
vs -0.24

Q1.25

arrow
arrow

N/A

-0.12
vs -0.18

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

+678%

11M  vs 1.4M

Q1.23

arrow
arrow

+1232%

47.6M  vs 3.6M

Q2.23

arrow
arrow

-7%

5.1M  vs 5.5M

Q3.23

arrow
arrow

+4%

7.3M  vs 7M

Q4.23

arrow
arrow

-98%

233K  vs 11M

Q1.24

arrow
arrow

-88%

5.7M  vs 47.6M

Q2.24

arrow
arrow

+2400%

128.2M  vs 5.1M

Q3.24

arrow
arrow

+459%

40.9M  vs 7.3M

Q4.24

arrow
arrow

+3202%

7.7M  vs 233K

Q1.25

arrow
arrow

+1%

5.8M  vs 5.7M

Return on EquityShape

status-upQoQ

Q4.22

arrow
arrow

-36%

-0.36
vs -0.37

Q1.23

arrow
arrow

+1%

0.01
vs -0.36

Q2.23

arrow
arrow

-17%

-0.17
vs 0.01

Q3.23

arrow
arrow

-52%

-0.52
vs -0.17

Q4.23

arrow
arrow

-122%

-1.22
vs -0.52

Q1.24

arrow
arrow

-199%

-1.99
vs -1.22

Q2.24

arrow
arrow

+72%

0.72
vs -1.99

Q3.24

arrow
arrow

-22%

-0.22
vs 0.72

Institutionnal OwnershipShape

status-upQoQ

Q1.23

arrow
arrow

66

66
vs 69

-4%

Q2.23

arrow
arrow

87

87
vs 66

32%

Q3.23

arrow
arrow

77

77
vs 87

-11%

Q4.23

arrow
arrow

76

76
vs 77

-1%

Q1.24

arrow
arrow

83

83
vs 76

9%

Q2.24

arrow
arrow

80

80
vs 83

-4%

Q3.24

arrow
arrow

82

82
vs 80

3%

Q4.24

arrow
arrow

81

81
vs 82

-1%

Earnings Growth

Latest News